What is US Stem Cell Debt-to-EBITDA?
Debt-to-EBITDA measures a company's ability to pay off its debt.
US Stem Cell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $8.27 Mil. US Stem Cell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.68 Mil. US Stem Cell's annualized EBITDA for the quarter that ended in Dec. 2022 was $-1.50 Mil.
US Stem Cell's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was -5.96.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for US Stem Cell's Debt-to-EBITDA or its related term are showing as below:
US Stem Cell Debt-to-EBITDA Historical Data
The historical data trend for US Stem Cell's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell Debt-to-EBITDA Chart
|
US Stem Cell Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Debt-to-EBITDA |
|
Get a 7-Day Free Trial
|
|
|
-9.94 |
-2.37 |
-3.12 |
-3.51 |
-4.13 |
|
US Stem Cell Quarterly Data
|
|
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
| Debt-to-EBITDA |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-16.03 |
-2.10 |
-5.42 |
-5.51 |
-5.97 |
Competitive Comparison of US Stem Cell's Debt-to-EBITDA
For the Biotechnology subindustry, US Stem Cell's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Debt-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Debt-to-EBITDA falls into.
US Stem Cell Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
US Stem Cell's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as
US Stem Cell's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2022) EBITDA data.
US Stem Cell (US Stem Cell) Business Description
Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
| Murphy William P Jr |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Gregory Knutson |
director |
14855 ABERDEN STREET NE, HAM LAKE MN 55304 |
| Mark P Borman |
director |
5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410 |
| Charles A Hart |
director |
19345 RHINESTONE STREET NW, ANOKA MN 55303 |
| Sheldon T. Anderson |
director |
1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149 |
| Kristin C Comella |
officer: Chief Science Officer |
1310 LEEWARD WAY, WESTON FL 33327 |
| A Jones Lee |
director |
54 LOCKE LAKE RD, FRIDLEY MN 55432 |
| Karl Groth |
director |
1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029 |
| Matthew J Fendrich |
officer: Vice President,Sales&Marketing |
482 PEACOCK LANE SOUTH, JUPITER FL 33458 |
| Alan P Timmins |
director |
1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660 |
| Bruce C Carson |
director |
11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448 |
| Howard J Leonhardt |
director, 10 percent owner, officer: Executive Chairman & CTO |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Bromley R Scott |
officer: VP of Public Relations |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Richard Iii Spencer |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
| Mike Tomas |
director |
13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
US Stem Cell (US Stem Cell) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your